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is known to be correlated with negative health outcomes in
pediatric primary care and subspecialties; it is not known
how poverty impacts HSCT outcomes.
Objective: To describe the baseline prevalence of poverty
and material hardship in the pediatric HSCT population at a
major referral center. To describe transplant-related work
disruptions and income losses stratiﬁed by federal poverty
level (FPL) in this patient population, and explore the rela-
tionship between family poverty and clinical outcomes.
Methods: Single institution, cross-sectional survey. Partici-
pants included 45 English-speaking, pediatric allogeneic
HSCT families whose children had undergone HSCT in the
prior twelve months and were alive at time of survey
administration. Eighty-seven percent of families approached
consented to study participation. This studywas approved by
the Dana-Farber Cancer Institute Institutional Review Board.
Results: Poverty prior to transplant was prevalent with 18
(40%) families reporting baseline incomes at or below 200%
FPL ($44,000 for a family of four). Parental work disruptions
due to HSCT were common across all income levels with 39
(87%) families reporting some disruption, and consequent
income losses were substantial for all families. Families at or
below 200% FPL were disproportionately impacted with 7
(39%) of the poorest families reporting transplant-associated
annual income losses of >40% as compared to 2 (18%) of the
wealthiest families (p¼0.006). Material hardship during the
post-transplant period was widespread, with 17 (38%) fam-
ilies reporting either food, housing, or energy insecurity.
Baseline family poverty level was not associated with length
of transplant admission, unplanned re-admissions, or ICU
stay in the 6-month post-transplant period in univariate
analysis. Poorer children, however, were more likely to
experience Graft Versus Host Disease (GVHD) of any grade in
the 6 month post-transplant period with eleven (61%) of
those at or below 200% FPL experiencing GVHD as compared
with 2 (18%) of the wealthiest (p¼0.01).
Conclusion: Baseline poverty is widely prevalent in the pe-
diatric HSCT population, and poverty may be associated with
the development of GVHD. Material hardship during the
post-transplant perioddincluding food, housing, or energy
insecuritydis widespread. Further studies aimed at under-
standing how these social determinants of health contribute
to HSCToutcomesmay provide targetable factors to decrease
transplant-associated morbidity and mortality.241
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Non-malignant hematologic disorders of childhood
comprise a number of various disorders including acquired
severe aplastic anemia (SAA), and inherited marrow failure
syndromes. Patients with such diseases who do not have
matched related donors fare poorly with allogeneic HSCT
from alternative donors and are at high risk for developing
chronic GvHD.We report 14 patients aged 0.7-18 years of age
(median 5.3 years) who received T-cell depleted HSCT fromalternative donors between April 2005 and May 2013. Dis-
eases included acquired SAA including PNH (N¼6), severe
chronic neutropenia (SCN)(N¼2), congenital amegakar-
yotycic thrombocytopenia (N¼2), Shwachman Diamond
syndrome (N¼1), autoimmune hemolytic anemia (N¼1),
chronic granulomatous disease (N¼1) and hemophagocytic
lymphohistiocytosis (N¼1). Two patients with SAA had
constitutional abnormalities and were therefore thought to
have possibly genetic diseases despite negative testing for
deﬁned disorders. Ten patients had long standing symp-
tomatic disease for> 1 year prior to transplant. Patients with
Fanconi anemia and dyskeratosis congenita were treated
with reduced intensity regimens and were not included.
Patients received one of 3 myeloablative regimens: Busulfan
Melphalan and Fludarabine (N¼2), Cyclophosphamide Thio
Flu (N¼3) or Mel, Thio Flu (N¼9). Patients received rabbit
ATG pre-transplant and ﬁlgrastim post transplant to promote
engraftment. Donors were unrelated HLA-matched donors
(N¼5), unrelated HLA-mismatched donors (N¼6) or related
HLA-mismatched donors (N¼2), and related phenotypic
matched donor (N¼1). Grafts included soybean agglutinin
negative, E-rosette negative bone marrow grafts (N¼5),
Isolex CD34+ E-rosette- peripheral blood stem cell grafts
(N ¼ 4), or CliniMACS CD34+ PBSC grafts (N¼5).
All 13 evaluable patients engrafted. Neutrophil engraftment
occurred on day +12 and platelet engraftment to 20,000 on
day +20 post transplant. Four patients died frommulti-organ
failure and/or infection (three of whom had a duration of
their disease of 2-7 years). One patient with SAA fully
engrafted with donor cells developed a pancytopenia post
transplant with secondary MDS in donor cells; this patient is
alive. Excluding one patient who is too early post transplant
and with a median follow-up of 2 years, 8 of 13 patients are
alive (OS 61%). None of these patients has evidence of GvHD.
These results should encourage proceeding to transplant
with chemotherapy-only cytoreductive regimens and T-cell
depleted stem cell transplants from alternative donors for
patients with nonmalignant hematologic disorders earlier in
the course of their disease.242
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Background: Hemophagocytic Lymphohistiocytosis (HLH) is
an immune regulatory disorder requiring allogeneic he-
matopoietic stem cell transfusion (HSCT) for long-term sur-
vival. More importantly, it is imperative to initiate treatment
early as delays in treatment can be associated with signiﬁ-
cant mortality. Unfortunately, there can be signiﬁcant over-
lap of the HLH diagnostic criteria with other non-HLH
conditions, thereby considerably delaying diagnosis and
therapy for HLH. Hence, surrogate markers are needed to aid
in the diagnosis and prevent delays in initiating therapy in
this life threatening disorder. Hypogammaglobulinemia has
been a less commonly reported feature of HLH. It has been
reported in SAP deﬁcient patients +/- HLH. More recently, it
has been reported in a few patients with XIAP deﬁciency and
STXBP2 mutations in association with colitis. We have
observed B-cell lymphopenia as well as hypogammaglobu-
linemia in patients with HLH at our institution. However, the
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at presentation have not been investigated so far in HLH.
Hence, we decided to retrospectively analyze lymphocyte
subsets and quantitative immunoglobulin levels in addi-
tional to traditional diagnostic markers at presentation in
patients with HLH.
Methods: We retrospectively analyzed the medical records
of patients who received a diagnosis of HLH at our institu-
tion, believed to be familial or secondary HLH. Patients with
SAP deﬁciency were excluded as hypogammaglobulinemia is
a known association. Patients who had received HLH therapy
prior to evaluation of lymphocyte subsets and immuno-
globulin levels were also excluded from the analysis. Data at
presentation was evaluable in 35 patients.
Results: Of the 35 patients, 26 had familial HLH and 9 had
secondary HLH. 25 patients underwent allogeneic HSCT.
Seven died secondary to complications post HSCT and 1
patient died prior to HSCT from refractory HLH. Identiﬁable
genetic mutations associated with HLH were found in 20
patients. Analysis of their immune phenotype in additional
to the diagnostic criteria revealed the following: 19(54%)
had B-cell lymphopenia, including 7(20%) who had both
T-cell and B-lymphopenia. 3(8%) patients had T-cell
lymphopenia. Even in patients with B and T cell lympho-
penia, the B-cell lymphopenia was proportionately lower.
Hypogammaglobulinemia (low IgG levels) was seen in 4
patients.
Discussion: Although we noted hypogammoglobulinemia in
a few patients, the predominant ﬁnding was the high inci-
dence of B-cell lymphopenia. Interestingly, B-cell lympho-
penia and hypogammaglobulinemia have also been noted
perforin deﬁcient mice with HLH at our institution (unpub-
lished data). In conclusion, this study suggests that B-cell
lymphopenia can serve as a surrogate marker for the diag-
nosis of HLH.243
Reduced-Intensity Conditioning and Umbilical Cord
Blood Transplantation in Children. Experience of a
Pediatric Hospital in Colombia
Marcela Estupinan, Mauricio Chaparro. HSCT Unit, Fundacion
Hospital de la Misericordia, Bogota, Colombia
Umbilical cord blood (UCB) has been shown to contain suf-
ﬁcient progenitor cells to provide durable engraftment in
children, and it provides an alternative stem cell source for
patients without matched related or unrelated donors.
We describe the preliminary results of a cohort of 16 pedi-
atric patients with a median age of 9 years (range 3 -18) with
haematological malignancies undergoing to a unrelated
umbilical cord blood transplant with a reduced-intensity
conditioning regimen of ﬂudarabine, melphalan, and
antithymocyte globulin.
All patients achieved hematologic recovery, the median
time to an absolute neutrophil count > 0.5 x 109/L was 20
days, and the median time to an unsupported platelet
count > 20 x 109/L was 32 days. Acute graft-versus-host
disease (GVHD) grade III-IV occurred in 37,5% of patients.
The 100-day TRM was 25%, and the 1 -year disease-free
survival was 58%.
Our ﬁndings support the use of reduced-intensity regimen in
pediatric patients with hematologic malignancies, however
the incidence of acute GVHD is a little higher than that re-
ported in other series so a better strategy for prophylaxis
against acute GVHD should be implemented.244
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X-linked adrenoleukodystrophy (X-ALD) is a demyelinating
disease caused by the deﬁciency of the ABCD1 gene that
encodes for a peroxisomal protein membrane. The most se-
vere form of X-ALD is the cerebral variant, which leads to
severe disability and death during the ﬁrst two decades. To
date, allogeneic hematopoietic stem cell transplantation
(HSCT) is the only treatment that has shown to signiﬁcantly
change the natural history of the disease, enhancing survival
and stabilizing neurological lesions and symptoms. In the
absence of a matched sibling or unrelated donor, hap-
loidentical family members might be an option in these
rapidly progressing diseases. Haploidentical HSCT has been
performed using a T cell depleted graft, but is often associ-
ated with higher rates of graft failure and delayed immune
reconstitution. Haploidentical HSCT using post-transplant
cyclophosphamide has been performed in series of malig-
nant and non-malignant diseases and has shown similar
outcomes compared to other alternative donor sources. Here
we show our experience with 8 patients with X-ALD treated
with haploidentical HSCT with post-transplant cyclophos-
phamide. Between november 2012 and august 2013, 8
patients with X-ALD (ages 6 to 18 years) underwent hap-
loidentical related HSCT in two different institutions, two
patients received two transplants with different related do-
nors. One patient received a second transplant after failure of
a double cord blood transplant. Pre-transplant MRI showed
Loes score of 2,5 to 18, all patients had neuropsychological
evaluation with performance IQ above 90. Donor was the
father (n¼7), the uncle (n¼2) or brother (n¼1). All patients
received reduced toxicity conditioning regimen consisted of:
ﬂudarabine 150 mg/m2, cyclophosphamide 29 mg/kg and
total body irradiation 2 Gy. Six patients received also rabbit
antithymocyte globulin 4,5 mg/kg. GVHD prophylaxis con-
sisted of cyclophosphamide 50 mg/kg/d on days +3 and +4,
tacrolimus and mycophenolate mofetil starting on day +5.
Seven patients engrafted, 13 to 19 days after transplant. One
patient had a primary graft failure and was not eligible for a
second transplant due to severe progression of neurological
symptoms. Two patients had secondary graft failure with
progressive loss of donor chimerism and were successfully
rescued with second haploidentical transplants using
different related donors. Four patients had grade II-IV acute
graft-versus-host disease and four patients had CMV reac-
tivations. One patient with grade III GVHD showed progres-
sion of neurologic symptoms of primary disease. Seven
patients are alive and engrafted from 3 to 11 months after
